■ Cannabidiol (CBD) for schizophrenia: promise or pipe dream?
J M Pierre
Current Psychiatry 2019: vol 18 (5): 12-16
■ Medicinal use of cannabis based products and cannabinoids
T P Freeman, C Hindocha, S F Green, M A P Bloomfield
BMJ 2019, vol 365: l1141
https://www.bmj.com/content/365/bmj.l1141
■ Digital technology for internet access by patients with early-stage schizophrenia in Spain: Multicenter Research Study
P Fernández-Sotos, A Fernandez-Caballero, P González et al
Journal of Medical Internet Research 2019, vol 21 (4)
https://www.jmir.org/2019/4/e11824/
■ Treatment-resistant schizophrenia: genetic and neuroimaging
Vita A, Minelli A, Barlati S, Deste G, Giacopuzzi E, Valsecchi P, Turrina C, Gennarelli M.
Front Pharmacol. 2019 Apr 16;10:402
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476957/
■ Overcoming barrier to effective management of tardive dyskinesia
Caroff SN.
Neuropsychiatr Dis Treat. 2019 Apr 4;15:785-794
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459148/
■ Trends in the scientific literatures on atypical antipsychotic drugs in the United Kingdom: a bibliometric study
Francisco López-Muñoz, Derek K. Tracy, F. Javier Povedano-Montero et al
Ther Adv Psychopharmacol. 2019; 9: 204512531882020
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378637/
■ Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidance
Emma Tay, Andreas Sotiriou, Garry G. Graham et al
Ther Adv Psychopharmacol. 2019; 9: 204512531983688
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444415/
■ Autistic symptoms in schizophrenia spectrum disorders: a systematic review and meta-analysis
De Crescenzo F, Postorino V, Siracusano M, Riccioni A, Armando M, Curatolo P, Mazzone L.
Front Psychiatry. 2019 Feb 21;10:78
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393379/
■ Childhood trauma in schizophrenia: current findings and research perspectives
Popovic D, Schmitt A, Kaurani L, Senner F, Papiol S, Malchow B, Fischer A, Schulze TG, Koutsouleris N, Falkai P.
Front Neurosci. 2019 Mar 21;13:274
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448042/
■ Barrier to using clozapine in treatment-resistant schizophrenia: systematic review
Saeed Farooq, Abid Choudry, Dan Cohen, Farooq Naeem, Muhammad Ayub
BJPsych Bull. 2019 Feb; 43(1): 8–16
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327301/
■ Role of paliperidone palmite 3-monthly in the management of schizophrenia: insights from clinical practice
Alicia Lopez, Jose Rey
Neuropsychiatr Dis Treat. 2019; 15: 449–456
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375110/
■ Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
Kristen Ward, Leslie Citrome
Neuropsychiatr Dis Treat. 2019; 15: 247–257
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339638/
■ Peripheral biomarkers for first-episode psychosis – opportunities from the neuroinflammatory hypothesis of schizophrenia
Nuno Trovão, Joana Prata, Orlando VonDoellinger, Susana Santos, Mário Barbosa, Rui Coelho
Psychiatry Investig. 2019 Mar; 16(3): 177–184
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444098/
■ Personalizing antipsychotic treatment: evidence and throughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders
Lex Wunderink
Ther Adv Psychopharmacol. 2019; 9: 2045125319836566
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457023/
■ Emotinal intelligence and schizophrenia spectrum disorders: a critical review
Martins, Fernanda de Marzio Pestana et al.
Trends Psychiatry Psychother., Mar 2019, vol.41, no.1, p.94-102
■ Schizophrenia: What non-psychiatrists physicians need to know?
T Queirós, F Coelho, L Linhares, D Telles-Correia
Acta Med Port 2019, vol 32 (1): 70-77
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10768/5592
■ Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
S Ijaz, B Bolea, S Davies et al
BMC Psychiatry 2018, vol 18: 275
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122457/
■ Women who suffer from schizophrenia: critical issues
M V Seeman
World J Psychiatry 2018, vol 8 (5): 125-136
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230925/
■ The acute efficacy of antipsychotic in schizophrenia: a review of recent meta-analysis
P M Haddad, C U Correl
Ther Adv Psychopharmacol 2018, vol 8 (11): 303-318
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180374/
■ Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective
S M Lawrie,
Ther Adv Psychopharmacol 2018, vol 8 (11): 319-326
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180375/
■ Schizotypy, schizotypic psychopathology and schizophrenia
M F Lenzenweger,
World Psychiatry 2018, vol 17 (1): 25-26
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775125/
■ Dr Paulo Fernando Leite
Cardiologia/Prevenção Cardiovascular
Estratificação de Risco Cardiovascular
Novo endereço:
Consultório: Rua Padre Rolim 815/sala 815
Tel: 33245518 (Consulta Particular/Unimed)
– Centro Médico Unimed BH/Contagem/Pedro I
Belo Horizonte/MG/Brasil
CRMMG: 7026
Email: pfleite1873@gmail.com